26 53. Nave AM, Tolin DF, Stevens MC. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. The Journal of clinical psychiatry. 2012;73(9):1179-1186. doi:10.4088/JCP.11m07564 54. Ebrahimi C, Koch SP, Friedel E, et al. Combining D-cycloserine with appetitive extinction learning modulates amygdala activity during recall. Neurobiology of Learning and Memory. 2017;142(pt.B):209-217. doi:10.1016/j.nlm.2017.05.008 55. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research. 2007;41(6):466-471. doi:10.1016/J.JPSYCHIRES.2006.05.006 56. Schienle A, Höfler C, Übel S, Wabnegger A. Emotion-specific nocebo effects: an fMRI study. Brain Imaging and Behavior. 2018;12(1):180-187. doi:10.1007/s11682017-9675-1 57. Field AP. Is conditioning a useful framework for understanding the development and treatment of phobias? Clinical Psychology Review. 2006;26(7):857-875. doi:10.1016/j.cpr.2005.05.010 58. LoLordo VM, Droungas A. Selective associations: Taste aversions and phobias . In: Klein SB, Mowrer RR, eds. Contemporary Learning Theories: Instrumental Conditioning Theory. Vol 2. Routledge; 1989. 59. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing exposure therapy: an inhibitory learning approach. Behaviour research and therapy. 2014;58:10-23. doi:10.1016/j.brat.2014.04.006 60. Schmid J, Bingel U, Ritter C, et al. Neural underpinnings of nocebo hyperalgesia in visceral pain: A fMRI study in healthy volunteers. NeuroImage. 2015;120:114-122. doi:10.1016/j.neuroimage.2015.06.060 61. Barad M, Gean PW, Lutz B. The Role of the Amygdala in the Extinction of Conditioned Fear. Biological Psychiatry. 2006;60(4):322-328. doi:10.1016/j.biopsych.2006.05.029 62. Sigurdsson T, Doyère V, Cain CK, LeDoux JE. Long-term potentiation in the amygdala: A cellular mechanism of fear learning and memory. Neuropharmacology. 2007;52(1):215-227. doi:10.1016/j.neuropharm.2006.06.022 63. Davis M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends in Pharmacological Sciences. 1992;13(C):35-41. doi:10.1016/0165-6147(92)90014-W 64. Davis M. The role of the amygdala in fear and anxiety. Annual Review of Neuroscience. 1992;15(1):353-375. doi:10.1146/annurev-neuro-080317-062245 65. Linnman C, Rougemont-Bücking A, Beucke JC, Zeffiro TA, Milad MR. Unconditioned responses and functional fear networks in human classical conditioning. Behavioural Brain Research. 2011;221(1):237-245. doi:10.1016/J.BBR.2011.02.045 66. Karos K, Meulders A, Vlaeyen JWS. Threatening social context facilitates painrelated fear learning. Journal of Pain. 2015;16(3):214-225. doi:10.1016/j.jpain.2014.11.014 67. Meulders A, Vlaeyen JWS. The acquisition and generalization of cued and contextual pain-related fear: An experimental study using a voluntary movement paradigm. Pain. 2013;154(2):272-282. doi:10.1016/j.pain.2012.10.025 68. Ohman A, Mineka S. Fears, phobias, and preparedness: toward an evolved module of fear and fear learning. Psychological review. 2001;108(3):483-522. 69. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta J-KK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses.
RkJQdWJsaXNoZXIy MTk4NDMw